Table of Content

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Type
3.2. Snippet by Therapy
3.3. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rising Prevalence of Melanoma
4.1.1.2. Rising Product Approvals and Market Access
4.1.2. Restraints
4.1.2.1. Underreporting of Melanoma Cancer
4.1.2.2. XX
4.1.3. Opportunities
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s Five Force Analysis
5.2. Epidemiology
5.3. Pricing Analysis
5.4. Pipeline Analysis
5.5. Patent Analysis
5.6. Regulatory Analysis
6. By Type
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
6.1.2. Market Attractiveness Index, By Type
6.2. Superficial Spreading Melanoma*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Nodular Melanoma
6.4. Lentigo Maligna Melanoma
6.5. Acral Lentiginous Melanoma
6.6. Others
7. By Therapy
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
7.1.2. Market Attractiveness Index, By Therapy
7.2. Surgery*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

7.3. Immunotherapy
7.3.1. Pembrolizumab
7.3.2. Nivolumab
7.3.3. Ipilimumab
7.3.4. Lifileucel
7.3.5. Others
7.4. Targeted Therapy
7.4.1. BRAF Inhibitors
7.4.2. MEK Inhibitors
7.4.3. KIT Inhibitors
7.5. Chemotherapy
7.6. Radiation Therapy
8. By Region
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
8.1.2. Market Attractiveness Index, By Region
8.2. North America
8.2.1. Introduction
8.2.2. Key Region-Specific Dynamics
8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.2.5.1. U.S.
8.2.5.2. Canada
8.2.5.3. Mexico
8.3. Europe
8.3.1. Introduction
8.3.2. Key Region-Specific Dynamics
8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

8.3.5.1. Germany
8.3.5.2. U.K.
8.3.5.3. France
8.3.5.4. Spain
8.3.5.5. Italy
8.3.5.6. Rest of Europe
8.4. South America
8.4.1. Introduction
8.4.2. Key Region-Specific Dynamics
8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.4.5.1. Brazil
8.4.5.2. Argentina
8.4.5.3. Rest of South America
8.5. Asia-Pacific
8.5.1. Introduction
8.5.2. Key Region-Specific Dynamics
8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.5.5.1. China
8.5.5.2. India
8.5.5.3. Japan
8.5.5.4. South Korea
8.5.5.5. Rest of Asia-Pacific
8.6. Middle East and Africa
8.6.1. Introduction
8.6.2. Key Region-Specific Dynamics
8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
9. Competitive Landscape
9.1. Competitive Scenario
9.2. Market Positioning/Share Analysis
9.3. Mergers and Acquisitions Analysis
10. Company Profiles
Key Market Players
10.1. Merck & Co., Inc.*
10.1.1. Company Overview
10.1.2. Product Portfolio
10.1.2.1. Product Description
10.1.2.2. Product Key Performance Indicators (KPIs)
10.1.2.3. Historic and Forecasted Product Sales
10.1.2.4. Product Sales Volume
10.1.3. Financial Overview
10.1.3.1. Company Revenue’s
10.1.3.2. Geographical Revenue Shares
10.1.3.3. Revenue Forecasts
10.1.4. Key Developments
10.1.4.1. Mergers & Acquisitions
10.1.4.2. Key Product Development Activities
10.1.4.3. Regulatory Approvals etc.
10.1.5. SWOT Analysis
10.2. Bristol-Myers Squibb Company.
10.3. Amgen, Inc.
10.4. IOVANCE Biotherapeutics, Inc.
10.5. Novartis AG
10.6. F. Hoffmann-La Roche Ltd
10.7. Pfizer Inc.
10.8. Immunocore Holdings plc.
10.9. Eisai Co., Ltd.
10.10. Delcath Systems, Inc.
* Similar data will be provided for each market player.
Emerging Market Players
10.11. Regeneron Pharmaceuticals Inc.*
10.11.1. Pipeline Products Description
10.11.2. Product Key Performance Indicators (KPIs)
10.11.3. Key Activities
10.11.4. Market Entry Timelines
10.11.5. Product Penetration Rate
10.11.6. Sales Estimation and Projections
10.12. Moderna, Inc.
10.13. Immatics N.V.
10.14. BioNTech SE.
10.15. Philogen S.p.A.
* Similar data will be provided for each market player.
LIST NOT EXHAUSTIVE
11. Appendix
11.1. About Us and Services
11.2. Contact Us